Should You Microdose a GLP-1? Benefits and Risks
Key takeaways:
- Microdosing is the off-label use of GLP-1 receptor agonists at doses lower than those approved for the treatment of diabetes or obesity. There are numerous reasons people may explore microdosing, including cost savings and minimizing side effects.
- Microdosing GLP-1 medications lacks clinical evidence, meaning doctors don’t have enough reliable data to confirm whether lower than approved doses are effective.
- Compounded GLP-1 formulations, which may be used for microdosing, carry additional risks, including uncertain drug quality and imprecise dosing that may be especially dangerous for people who also take insulin.
GLP-1 receptor agonists like Ozempic and Mounjaro have reshaped the conversation around weight loss and diabetes management. Now, a growing number of people are experimenting with something even further outside the guidelines: taking these medications at a fraction of the approved dose.
Microdosing, which means taking a medication at a dose smaller than the approved dose, is not FDA-approved, but has gained traction on social media, in wellness circles, and now, in clinical conversations. But does it work – and is it safe?
Why consider microdosing?
You might wonder why someone would want to take lower than the recommended standard treatment for GLP-1 medications like Ozempic. But there are some pretty important reasons, like cost savings, minimizing side effects, preventive benefits, or a combination.
Cost is a major one. In the U.S., list prices for GLP-1-based medications are up to $1,000 or more a month before insurance. Whether you pay that depends on your coverage, prior authorization, and savings programs, but some people microdose simply because that’s the most affordable option for treatment.
Side effects are another. Studies find that nearly half of people who start a GLP-1 stop due to cost or side effects like nausea, vomiting, or diarrhea.
“I could see a scenario where someone is very sensitive to the gastrointestinal side effects of GLP-1s, where microdosing might be considered,” said Dr. Judy Korner, an endocrinologist and director of the Metabolic and Weight Control Center at Columbia University Irving Medical Center. “But that’s usually not an issue at the very low starting dose. What we do in that scenario is keep patients at the lowest dose before escalating, to let their body adjust to the medication.”
While the low and slow method can work for many people, with side effects often leveling out over time, for some, they aren’t tolerable, even at the lowest starting dose.
Dr. Marilyn Tan, chief of the Endocrine Clinic at Stanford Health Care, said more commonly she’s seeing people microdose for weight loss and weight maintenance.
“Sometimes, it's patients who need the GLP-1 agonist for diabetes management but can't afford to lose too much weight,” she said.
That was the case for diaTribe CEO Jim Carroll, who microdoses tirzepatide (Mounjaro) to maintain the blood sugar benefits and protective effects for the heart and kidneys. Carroll initially started taking a GLP-1 to help manage his recently diagnosed type 2 diabetes and lose a bit of weight. But he lost too much weight too fast, to the point where he knew he couldn’t continue taking the medication, even at the baseline dose. He was reluctant to quit, not just because of the blood sugar benefits, but because of the overall health effects these medications have on the other parts of the body, including the heart, liver, and kidneys.
“How do you stay on the drug at a level that won't cause weight loss, but does actually convey these cardiorenal benefits? Because I want those benefits,” he said. Any potential benefits from microdosing have not been scientifically proven, but for Carroll, it’s worth trying (under careful supervision with his doctor).
GLP-1s are also intended to be taken long-term; research finds that most people who stop taking treatment typically regain at least some, if not all, of the weight lost and may lose blood sugar and other related benefits.
“People often ask whether they will need to stay on these medications forever. I understand the question. I asked it, too,” Carroll said. “But over time, I found myself asking a different one: If this medication is helping me lose weight, keep it off, and improve my blood sugar, and it is safe for me, why would I stop?”
Is microdosing safe?
Research is limited on whether microdosing helps maintain weight loss, blood sugar, and the other protective benefits of GLP-1s at standard doses, so experts can’t say for certain yet if it “works.” But more importantly, for someone exploring microdosing for the first time, they might wonder: Is it safe?
"In theory, it's safe since it's an FDA-approved medication at a lower dose," said Tan. "But microdosing has not been well studied in clinical trials, and most of the data is anecdotal."
She said that when someone asks her about microdosing a GLP-1, she advises that, since it's off-label (meaning not approved by the FDA), carefully monitoring their blood sugar, weight, and symptoms is essential.
For Korner, what’s particularly worrying when it comes to microdosing is the lack of research, given that these medications carry proven cardiovascular and kidney benefits that have never been evaluated at microdose levels.
“So, it's not all about weight, it's not all about blood sugar,” she said. “It's about these broader potential health benefits."
Korner added that she also worries about the safety and quality of compounded GLP-1 formulations sometimes used to extract the smaller doses. With this method, it's not always easy to know exactly how much medication is being taken. This can be especially dangerous, she said, if someone who also takes insulin accidentally takes too high a dose, putting them at risk for hypoglycemia.
“I would be concerned about the potential safety issues of getting medication from non-FDA-approved compounding pharmacies,” she said. “Some may be completely fine, but you don’t necessarily know what you’re getting.”
What to do if you can’t stay on a GLP-1
Though microdosing is not approved by the FDA, it is something you can discuss with your healthcare provider if you want to stay on a GLP-1 but can’t, whether due to cost, side effects, or other reasons. Most insurers cover GLP-1 treatment for diabetes, but if cost is a barrier, companies often offer savings programs that can help.
If you need to stop taking a GLP-1 altogether, it’s important to make the transition safely to minimize any impacts on health, as some benefits of these treatments cannot be replaced by other means. Focusing on a protein-rich diet and getting regular exercise may help preserve some of the benefits.
Researchers are currently testing out new drugs in clinical trials aimed at reducing the GLP-1 side effects, which are one of the main reasons people say they stop taking GLP-1 medicines.
The bottom line
Since the earliest days of GLP-1s with exenatide in 2005, through the past two decades to Ozempic and Mounjaro, the field has come a long way and will continue to evolve. Until then, experts said it’s important to remember that research around microdosing is limited, and should only be done under the recommendation and guidance of a healthcare professional.
diaTribe does not provide medical diagnosis, advice, or treatment. Talk with your healthcare team before starting, stopping, or changing any medication.
Learn more about diabetes treatments here: